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Abstract
Purpose The purpose of this study was to investigate the cor-
relation between serum levels of serum apolipoprotein M
(ApoM), A5 (ApoA5), and high-density lipoprotein (HDL)
in patients with obstructive sleep apnea hypopnea syndrome
(OSAHS) and study the effects of nasal continuous positive
airway pressure treatment on these serum biomarkers.
Methods Thirty OSAHS patients and 15 non-OSAHS pro-
bands as control were selected for the study. Serum HDL,
ApoM, and ApoA5 levels in two groups were detected; dif-
ferences and association among them were analyzed. Patients
with moderate and severe OSAHS underwent 3-month auto-
continuous positive airway pressure treatment, and a compar-
ative study was conducted to investigate the changes in blood
lipids, serum ApoM, and ApoA5.
Results In comparison to the control group, the HDL, ApoM,
and ApoA5 serum levels were lower (P<0.05). HDL was
positively correlated to ApoM and ApoA5 (P<0.001), and
ApoM was positively correlated to ApoA5 (r = 0.536,
P<0.001). HDL, ApoM, and ApoA5 were significantly in-
creased in the patients of moderate and severe OSAHS after
auto-continuous positive airway pressure treatment for
3 months (P<0.05).
Conclusions The HDL level was significantly lower in
OSAHS patients. The decrease in serum ApoM and ApoA5
in OSAHS patients was correlated to the severity of OSAHS
and HDL levels. Auto-continuous positive airway pressure
treatment increased serum levels of ApoM, ApoA5, and
HDL in OSAHS patients.
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Introduction
Obstructive sleep apnea hypopnea syndrome (OSAHS) is a
disorder with a high incidence and potential risks, manifested
as snoring accompanied with respiratory pauses, hypopnea,
shallow breathing, recurrent hypoxemia, and hypercapnia ac-
idosis during the night [1–3]. This sleep structure disorder
might lead to daytime sleepiness and multiple organ damage,
as well as seriously affecting quality of life [4].
The adverse effects of OSAHS include its high incidence
and the involvement of multiple organs and systems [5–7], as
well as its close association with cardiovascular diseases such
as hypertension, coronary heart disease, and atherosclerosis
[8, 9]. OSAHS is an important causative factor for coronary
heart disease, independent from other factors such as age,
obesity, smoking, diet, and genetic background. Lavi [10]
and Svatikova [11] discovered that the increased incidence
of cardiovascular disease in OSAHS patients might be related
to their lipid metabolism disorder. Therefore, a thorough in-
vestigation of a possible correlation between OSAHS and the
lipid metabolism disorder is needed. It has been shown that the
blood lipid profile of OSAHS patients is abnormal, manifesting
as a significant increase in triglyceride (TG), total cholesterol
(CHOL), very low-density lipoprotein (VLDL), low-density
lipoprotein (LDL), apolipoprotein B (ApoB), and lipoprotein
a (Lpa) in serum, while high-density lipoprotein (HDL) and
apolipoprotein A (ApoA) levels decrease. This abnormal blood
lipid profile might be a causative factor of cardiovascular
disease [12–14].
ApoA5 belongs to the apolipoprotein superfamily discov-
ered in 2001 by Pennacchio et al. [15, 16]. The accumulated
animal studies and epidemiological studies indicate that
ApoA5 is closely connected with lipid metabolism. ApoA5
causes a decrease in the serum levels of TG and is considered
as a negative regulator of TG [15]. ApoA5 was reported to be
associated with HDL, VLDL, and chylomicron in human se-
rum [17]. Furthermore, it was also suggested that ApoA5 pro-
duced in liver tissue could promote ApoA1 elevation in the
serum, resulting in increased serum levels of HDL-C. ApoA5
also enhances cholesterol release frommacrophages [18]. The
lecithin cholesterol acyltransferase (LCAT), which plays a vi-
tal role in the maturation of HDL, was reported to be positive-
ly associated with ApoA5 [19]. All these findings suggest that
ApoA5 might promote HDL maturation, thus regulating the
anti-atherosclerosis function of HDL by manipulating the size
and subgroups of HDL in the serum.
Apolipoprotein M (ApoM) is a newly discovered apolipo-
protein which has a special structure and is considered to play
an important role in the metabolism of HDL and the anti-
atherosclerosis process [20]. HDL biosynthesis consists of a
series of complicated linked reactions, with various apolipo-
proteins involved. The mouse model study by Wolfrum et al.
[21] showed that the expression of ApoM in liver was reduced
by 90% through RNAi against ApoMmRNA, which resulted
in a significant decrease of ApoM in serum and a 25 %
decrease of serum HDL-C.
OSAHS and hyperlipidemia are common but typically
neglected by patients. The correlation between these two con-
ditions is still in early stages of evaluation. ApoM and ApoA5
are apolipoproteins which have been gradually investigated in
the recent years; however, clinical research documenting the
relationship between the levels of ApoM, A5, and HDL-C in
the serum of OSAHS patients has not been published yet.
Therefore, this study aimed at measuring the serum levels of
ApoM, A5, and HDL in OSAHS patients and investigating
the influence of nasal continuous positive airway pressure
treatment on ApoM and ApoA5.
Materials and methods
Patients
This was a retrospective study of 45 patients under examina-
tion by polysomnography (PSG) in the sleep laboratory of the
Second Xiangya Hospital of Central South University in
China, between January 2013 and October 2013. Among the
45 subjects, 30 were patients with mild, moderate, and severe
OSAHS (Apnea Hypopnea Index (AHI) ≥ 5), as well as
additional 15 probands as controls (AHI<5).
AHI measures the number of apnea and hypopnea events
per hour of sleep. The apneas lasting at least 10 s are associ-
ated with a decrease in blood oxygenation. The OSAHS was
diagnosed based on the following manifestations: recurrent
apnea and hypopnea occurring more than 30 times during
the night lasting 7 h, AHI>5, obstructive apnea accompanied
with snoring, sleep apnea, and daytime sleepiness. The
5≤AHI <15 range of values was defined as mild OSAHS,
the 15≤AHI <30 range was defined as moderate OSAHS,
and AHI≥30 was defined as severe OSAHS [22].
Exclusion criteria for all subjects included a history of
smoking or alcoholism (no drinking history or drinking
<140 g/week for men and <70 g/week for women was
allowed); myocardial infarction, unstable angina pectoris, val-
vular heart disease, cardiomyopathy, severe arrhythmia,
stroke, tumor, severe renal insufficiency, severe lung diseases,
infections, trauma, or surgeries 2 weeks prior to the study.
For patients receiving medications, oral antihypertensive
agents were continued, including amlodipine and perindopril
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in patients with high blood pressure; there were no oral
medications being supplied to the patients with diabetes.
Written informed consent was obtained from all subjects
before the study and the study was performed in accordance
with the ethical standards laid down in the 1964Declaration of
Helsinki and its later amendments. The research protocol was
approved by the Ethics Committee of Department of Geriatric
at the Second Xiangya Hospital, Central South University in
China.
General information collection
General information, including disease history, family history,
smoking or drinking habits, and medication history during the
recent 6 months was collected through questionnaires.
Physical measurements such as height, weight, waist circum-
ference (WC), hip circumference (HC), neck circumference
(NC), systolic blood pressure (SBP), diastolic blood pressure
(DBP), body mass index (BMI), and waist hip ratio (WHR)
were also archived for analysis.
Polysomnography
The sleep patterns of patients were monitored by digital
polysomnography (REMBRANDT, Medcare, Buffalo, NY,
USA) for more than 7 h during the night; meanwhile, electro-
encephalogram (EEG), electromyogram (EOG), electromyog-
raphy (EMG), electrocardiogram (ECG), snoring, oronasal
airflow and thoracoabdominal motion, and fingertip oxygen
saturation (nocturnal mean and minimum SaO2) were also
recorded.
The results from polysomnography recordings, including
the following parameters: AHI, total sleep apnea time, sleep
low ventilation time, the longest sleep respiratory pause time,
lowest oxygen saturation (LSaO2), mean oxygen saturation
(MSaO2), the percentage of blood oxygen saturation below
90 % during sleep (T-SaO2<90 %), night awakening times
and duration, were all computer-analyzed and curated
manually before releasing the data.
Continuous positive airway pressure
The patients with moderate to severe OSAHS received a ther-
apeutic trial of auto-continuous positive airway pressure
(RESMED, Sydney, Australia) during the next 3 months.
Collection and storage of serum samples
Blood samples were obtained from each participant after the
PSG test. They were obtained once again from patients after
the 3-month auto-continuous positive airway pressure treat-
ment. Serum from 3 mL of venous blood, drawn from the
ulnar vein, the supernatant was stored in the −70 °C freezer
after 10 min of centrifugation at a speed of 3000 rpm.
Serum samples measurement
Serum levels of CHOL, TG, HDL-C, and LDL-C were mea-
sured using the automatic biochemical analyzer, type 7600
(Hitachi, Tokyo, Japan).
ELISA kits (R&D Systems, Minneapolis, MN, USA) were
used in the current study for determination of serum ApoM
and ApoA5 levels. Briefly, the serum sample and biotinylated
antibody were added to ELISA plates sequentially andwashed
by PBS or TBS. Subsequently, the antibody-antigen complex
was recognized using streptavidin labeled peroxidase and vi-
sualized by TMB after thoroughly washing with BS or TBS.
TMB turned blue under peroxidase treatment and later
changed to yellow under acidic conditions. The color depth
reflects the concentration of the tested substrate; the darker the
color, the higher the concentration. The automatic ELISA
microplate reader (Rayto Life and Analytical Sciences Co.,
Ltd. Shenzhen, China) was utilized for quantitation.
Statistical analysis
SPSS13.0 software was utilized in this study. Quantitative
data fitting a normal distribution pattern were presented as
mean ±SD. The data which was not normally distributed
was presented as the median and range. The data not fitting
a normal distribution were subjected to natural logarithm op-
eration or geometric mean calculation before statistical analy-
sis. The t test and variance analysis were used to compare data
means, while the χ2 test was utilized for ratio comparison. The
HDL-C, ApoM, and ApoA5 levels in controls and patients
with different severity of OSAHS were analyzed by
Kruskal-Wallis test. The multivariate stepwise regression
analysis was adapted for multiple factors’ analysis, with
P<0.05 considered as statistically significant.
Results
Clinical information
There were no significant differences between the two studied
groups in terms of age, gender, BMI, and disease distribution.
The neck circumference, the waist hip ratio, the AHI, and the
serum level of TGwere higher in the OSAHS group compared
with controls. Serum levels of HDL, ApoM, and ApoA5 were
lower in the OSAHS group, and the mean nocturnal SaO2 and
minimum SaO2 were significantly lower in the OSAHS group
in comparison to the controls. There was no significant differ-
ence between the two groups with respect to serum levels of
CHOL and LDL-C (Table 1).
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The relationship between OSAHS severity and ApoM
and ApoA5 serum levels
The AHI was positively correlated to TG and negatively
correlated to HDL, ApoM, and ApoA5 in all participants.
The HDL-C level was significantly lower in severe
OSAHS than in mild OSAHS (P < 0.05) (Fig. 1a) and
the ApoM and ApoA5 levels were both significantly low-
er in each severity of OSASHS patients than in the
healthy controls (P< 0.05) (Fig. 1b, c). The mean noctur-
nal SaO2 and minimum SaO2 were negatively correlated
to serum levels of TG in all participants; whereas, the
mean nocturnal SaO2 and minimum SaO2 were positively
correlated to serum levels of HDL, ApoM, and ApoA5
(Table 2).
Correlations and multivariate stepwise regression analysis
for ApoM, ApoA5, and the other parameters
A positive correlation was observed between serum AHI and
TG in all patients, while negative correlations were observed
between AHI and HDL-C, ApoM, and ApoA5 in all patients
(P<0.05). The serum level of TGwas negatively correlated to
the mean nocturnal oxygen saturation (SaO2) and minimum
SaO2, while HDL, ApoM, and ApoA5 were positively corre-
lated to the mean nocturnal oxygen saturation (SaO2) and
minimum SaO2 (P<0.05). HDL was positively correlated to
ApoM and ApoA5 (P<0.001), and ApoM was positively
correlated to ApoA5 (r=0.536, P<0.001). The serum TG
level was significantly reduced in patients with moderate
and severe OSAHS after a 3-month treatment with auto-
Table 1 General information of
OSAHS and control groups OSAHS group (n= 30) Control group (n = 15) P
Gender (man:woman) 23:07 12:03 NS
Age (year) 38 ± 15 39 ± 14 0.746
BMI (kgW) 27± 3 26 ± 2 0.153
Neck circumstance (m) 0.58 ± 0.06 0.38± 0.03 0.004*
Waist hip ratio 0.96 ± 0.04 0.86± 0.06 0.001*
Complicated with hypertension (case) 6 3 NS
Complicated with diabetes (case) 4 1 NS
AHI 30± 18 3 ± 1 <0.0001*
Mean SaO2 (%) 91± 2.09 96 ± 2.53 <0.001*
Minimum SaO2 (%) 68± 18.17 88 ± 5.49 <0.0001*
CHOL (mmol/L) 4.36 ± 1.12 4.38± 1.38 0.325
TG (mmol/L) 2.17 ± 1.03 1.48± 0.55 0.025*
HDL-C (mmol/L) 0.88 ± 0.29 1.56± 0.27 0.015*
LDL-C (mmol/L) 2.50 ± 0.75 2.49± 0.83 0.684
ApoM (pg/mL) 921.05± 382.33 1708.81 ± 1584.38 0.027*
ApoA5 (pg/mL) 3221.31 ± 62.51 5776.11 ± 94.3 0.028*
*P< 0.05 indicates statistically significant difference
Fig. 1 HDL-C, ApoM, and ApoA5 levels in healthy probands and patients with different severity of OSAHS. a HDL-C, b ApoM, and c ApoA5 levels
in subjects. #P< 0.05 vs. mild OSAHS patients. *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001 vs. healthy probands
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continuous positive airway pressure (P<0.05), while HDL,
ApoM, and ApoA5 were increased significantly (P<0.05).
The multivariate stepwise regression analysis was
performed with ApoM as the dependent variable and
AHI, mean SaO2, minimum SaO2, HDL-C, and ApoA5
as independent variable. It was also performed with
ApoA5 as the dependent variable and the AHI, mean
SaO2, minimum SaO2, HDL-C, and ApoM as indepen-
dent variables. A good correlation was found between
ApoM and HDL-C, and mean SaO2 (β = 0.020,
95%CI = 0.380–0.612, P = 0.0003), and also between
ApoA5 and HDL-C, and mean SaO2 (β = 0.502,
95%CI = 0.260–0.562, P = 0.000).
The effects of auto-continuous positive airway pressure
treatment on patients with moderate or severe OSAHS
Twenty patients with moderate or severe OSAHS all complet-
ed the 3-month auto-continuous positive airway pressure
treatment. The treatment lasted more than 7 h every night.
The symptoms of daytime sleepiness, fatigue, and night awak-
enings due to shortness of breath, dizziness, and dry mouth
upon awakening were all significantly alleviated. The AHI,
mean nocturnal SaO2, and minimum SaO2 were all improved
significantly (P<0.05). The serum level of TG was reduced
significantly after auto-continuous positive airway pressure
treatment (P<0.05), while there was no significant change
in the BMI, neck circumference, and waist hip ratio. The
serum levels of CHOL and LDL improved after treatment,
but the difference remained insignificant (Table 3).
Discussion
The effect of OSAHS on blood lipid metabolism
Epidemiological studies show that OSAHS incidence in the
40–60-year age group ranges between 5 and 10 % [23]. A
survey found that 9 % of women and 24 % of men aged
between 30 and 60 years have experienced sleep apnea, while
2% of women and 4% ofmen are diagnosed with sleep apnea
syndrome [24]. OSAHS can affect multiple organs, leading to
functional and organ damage, an impaired quality of life and a
shortened life span. It has also been determined that OSAHS is
an independent risk factor for various systemic diseases
[15, 16].
Lipid metabolism disorder refers to elevated serum lipid
levels, including increased levels of CHOL, TG, and HDL-
C, and a decreased level of LDL-C. The main influencing
factors include diet, lifestyle, age, gender, obesity, as well as
genetic and psychological factors. In the current study, there
was no significant difference between two groups in terms of
age and gender; therefore, the potential influence of these two
parameters on lipid metabolism was excluded. Our findings
indicate that serum TG and HDL-C levels are significantly
different in the OSAHS and control groups (P < 0.05).
Significantly increased TG level and significantly decreased
HDL-C level were found in the OSAHS group compared to
controls, which was consistent with an earlier study [25].
The AHI is the objective parameter used to classify the
severity of OSAHS. Chronic intermittent hypoxia is thought
to be a primary trigger for hypertension in OSAHS and is
likely to be implicated in activating inflammatory pathways
that result in many comorbidities of OSAHS [26, 27]. The
severity of nocturnal hypoxia is reflected by both mean noc-
turnal SaO2 and minimum SaO2 values. In the present study,
the increased serum TG level was positively correlated with
the AHI and negatively correlated with nocturnal mean SaO2
and minimum SaO2. On the other hand, the decreased serum
HDL-Cwas negatively correlated with the AHI and positively
correlated with the mean nocturnal SaO2 and minimum SaO2.
This implies that more severe OSAHS has more significant
lipid metabolism disorder. Accumulated studies indicate that
OSAHS patients often present with hyperlipidemia. However,
it remains unknown whether OSAHS is an independent
influencing factor for the lipid metabolism disorder or what
is the relationship between OSAHS and hyperlipidemia.
Some researchers have postulated that the OSAHS patients
also suffer from the blood glucose metabolism disorder and
non-insulin-dependent diabetes mellitus, which might result
Table 2 Correlations between
serum parameters AHI Mean SaO2 Minimum SaO2 ApoM Apo-A5
r P r P r P r P r P
TG 0.45 0.002* −0.464 0.005* −0.565 0.001* 0.494 0.000* 0.562 0.000*
CHOL 0.063 0.749 0.064 0.951 0.365 0.32 0.202 0.277 0.213 0.523
HDL −0.566 0.000* 0.471 0.000* 0.477 0.000* 0.56 0.000* 0.483 0.000*
LDL 0.063 0.754 0.154 0.75 0.369 0.33 0.257 0.171 0.292 0.3
ApoM −0.397 0.006* 0.421 0.015* 0.533 0.003* 0.536 0.000*
ApoA5 −0.357 0.015* 0.38 0.041* 0.395 0.012*
*P< 0.05 indicates statistically significant difference
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in hyperglycemia and subsequent hyperlipidemia due to
energy conversion [28].
It was found that OSAHS patients also have insulin resis-
tance, which might lead to an increase in CHOL and TG and a
decrease in HDL-C. Auto-continuous positive airway pressure
treatment is so far the safest and most effective therapy for
moderate and severe OSAHS. Sleep hypoxia may be alleviat-
ed by applying air pressure to eliminate upper airway collapse,
adjust sleep habits, and result in improvement of OSAHS
symptoms. Our findings also indicate that auto-continuous
positive airway pressure could effectively decrease hyperlip-
idemia in obese OSAHS patients. The symptoms of daytime
sleepiness, fatigue, and night awakenings due to shortness of
breath, dizziness, and drymouth upon awakening in the morn-
ing were all significantly alleviated with treatment; the AHI,
mean nocturnal SaO2, and minimum SaO2 all significantly
improved. The serum level of TG and HDL-Cwas significant-
ly reduced after auto-continuous positive airway pressure
treatment, while there was no significant change in the BMI,
neck circumference, and waist hip ratio. These findings fur-
ther indicate that there may be a relationship between the
blood lipid metabolism disorder and OSAHS, which was in-
dependent from obesity. The serum gamma-glutamyl
transpeptidase (GGT) improved after auto-continuous posi-
tive airway pressure treatment but not significantly, which
might be due to the short treatment period in the present study.
Although it is already known that OSAHS is correlated with
hyperlipidemia and insulin resistance, there was no significant
difference between the two groups in terms of CHOL and
LDL-C. However, significant differences were found with
respect to TG and HDL-C.
The effect of OSAHS on serum ApoM and ApoA5
In the current study, a positive correlation between serum
ApoM and ApoA5 and HDL was observed, indicating that
OSAHS might be involved in lipid metabolism disorder by
regulating ApoM and ApoA5 on HDL. However, this
speculation is in need of further confirmation.
Meanwhile, the positive correlation between serum ApoM
and ApoA5 and HDL indicates that ApoM and ApoA5 might
be the apolipoproteins contributing to HDL abnormality in
OSAHS, which is in accordance with previously published
data [29].
The serum levels ApoM and ApoA5 in the OSAHS group
were significantly lower in comparison to the control group
after age, gender, and BMI parameters were matched. This
finding indicates that the more severe the OSAHS, the lower
the serum levels of ApoM and ApoA5. In the present study,
auto-continuous positive airway pressure treatment lowered
serum ApoM, ApoA5, and HDL levels significantly, further
confirming the correlation between OSAHS severity and the
serum levels of ApoM and ApoA5.
Multivariate regression analysis indicated that the serum
ApoM and ApoA5 levels are correlated with mean SaO2,
which reflects the severity of OSAHS. Serum ApoM,
ApoA5, and HDL levels in OSAHS patients after treatment
strongly indicated that ApoM and ApoA5 are the important
bridge between OSAHS and HDL. Given the high mortality
rate and severe adverse effects on organs, OSAHS has gradu-
ally gained importance in the health care field. There are many
common features between OSAHS and hyperlipidemia—both
are common diseases strongly associated with obesity, aging,
glucose metabolism disorder, and hypertension. OSAHS is
usually concurrent with hyperlipidemia, although it has been
found that OSAHS and its related hypoxia could cause the
lipid metabolism disorder independently from obesity [30].
This study has some limitations. As a retrospective, cross-
sectional study, there may be some bias in the results.
Therefore, further study is needed to fully investigate the
cause and effect of cardiovascular problems in OSAHS and
whether these are directly related to lipid metabolism disorder.
Table 3 Serum parameters
before and after auto-continuous
positive airway pressure treatment
in moderate and severe OSAHS
Before treatment (n= 20) After treatment (n = 20) P
BMI (kgW) 27.74 ± 2.14 27.44 ± 2.26 0.133
Neck circumference (m) 0.55 ± 0.36 0.58± 0.03 0.425
Waist hip ratio 0.94 ± 0.25 0.91± 0.36 0.198
AHI 37.68 ± 14.10 8.09± 5.04 0.001*
Mean SaO2 (%) 91.14 ± 2.34 95.96 ± 2.42 0.012*
Minimum SaO2 (%) 66.29 ± 18.49 87.29 ± 5.12 0.042*
CHOL (mmol/L) 3.84 ± 0.43 3.39± 1.03 0.485
TG (mmol/L) 2.62 ± 1.31 1.26± 0.53 0.017*
HDL-C (mmol/L) 0.89 ± 0.44 1.35± 0.27 0.018*
LDL-C (mmol/L) 1.78 ± 0.65 1.69± 0.80 0.339
ApoM (pg/mL) 881.6 ± 291.47 1934.15 ± 1120.22 0.016*
ApoA5 (pg/mL) 104.97± 59.89 229.94± 109.49 0.013*
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The number of included subjects was low and included many
more males than females; this gender difference in the popu-
lation is likely to be influenced by males having an increased
likelihood of having OSAHS [23, 24].
In the present study, the serum HDL levels decreased in
OSAHS patients along with serum ApoM and ApoA5 levels,
indicating that ApoM and ApoA5, which are involved in the
HDL disorder, may also be regulated by intermittent hypoxia.
This new finding may help facilitate an in-depth study on
OSAHS and hyperlipidemia and open up a new therapeutic
option.
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